2024
Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells
Bangert C, Alkon N, Chennareddy S, Arnoldner T, Levine J, Pilz M, Medjimorec M, Ruggiero J, Cohenour E, Jonak C, Damsky W, Griss J, Brunner P. Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells. Nature Communications 2024, 15: 2839. PMID: 38565563, PMCID: PMC10987549, DOI: 10.1038/s41467-024-46540-0.Peer-Reviewed Original ResearchConceptsHead and neck dermatitisAtopic dermatitisNeck dermatitisT cellsHealthy control skinType 2 inflammationDupilumab treatmentImmune signaturesReceptor upregulationActivation markersClinical efficacyPunch biopsyHistopathological featuresDe novo appearanceIL-22Single-cell RNA sequencingDrug effectsDupilumabSide effectsControl skinDermatitisKeratinocyte activationUntreated ADTreatmentRNA sequencing
2023
Machine learning analysis of pretreatment skin biopsies predicts nonresponse to dupilumab in patients with eczematous dermatitis
Murphy M, Hwang E, Singh K, Lee T, Cohen J, Damsky W. Machine learning analysis of pretreatment skin biopsies predicts nonresponse to dupilumab in patients with eczematous dermatitis. British Journal Of Dermatology 2023, 190: 132-134. PMID: 37818837, DOI: 10.1093/bjd/ljad389.Peer-Reviewed Original ResearchBaseline skin cytokine profiles determined by RNA in situ hybridization correlate with response to dupilumab in patients with eczematous dermatitis
Singh K, Valido K, Swallow M, Okifo K, Wang A, Cohen J, Damsky W. Baseline skin cytokine profiles determined by RNA in situ hybridization correlate with response to dupilumab in patients with eczematous dermatitis. Journal Of The American Academy Of Dermatology 2023, 88: 1094-1100. PMID: 36780951, DOI: 10.1016/j.jaad.2022.12.052.Peer-Reviewed Original ResearchConceptsEczematous dermatitisHistologic featuresTreatment selectionType 1Type 3 inflammationInflammatory skin diseaseCertain histologic featuresSitu hybridization correlatesClinical responseNonresponder groupCytokine profileCytokine stainingAtopic dermatitisCytokine RNAEczematous disordersSitu hybridizationDupilumabIL13 expressionSkin diseasesType 2PatientsDermatitisNonrespondersMolecular heterogeneityImproved response